Exogenus Unveils Standardized QC Workflow for Cord Blood EV Therapy

Exogenus Therapeutics, a company developing umbilical cord blood–derived extracellular vesicles for inflammatory and degenerative conditions, has built a quality-control workflow that replaces costly whole-molecular profiling with a standardized, sustainable assay panel — a blueprint the company shared at Cell & Gene Therapy International Europe.

The company’s argument is that producing a non-conventional product should not be a barrier to streamlined manufacturing and quality-control analytics. “I think our main message to the corporate EV community is it’s possible to develop and produce an extracellular vesicle-based product that falls outside the mainstream,” said Andreia Silva, PhD, head of research at Exogenus, who spoke at the conference.

Exogenus simplifies EV batch testing for clinical use

  • Each extracellular vesicle carries a cargo of thousands of lipid, protein, and metabolite species along with DNA and RNA, any of which could exert an effect after delivery to a target organ.
  • Because each vesicle is made of thousands of different molecules, checking every batch thoroughly has been expensive; Exogenus shows a simpler, standardized testing approach can work.
  • The company is moving toward the clinical stage of development.

Why donor variability makes this product hard to make

Exogenus builds therapies aimed at inflammatory and degenerative conditions from umbilical cord blood starting material. Silva explained that this raw material shows greater variability than conventional EV cell sources because it comes from multiple donors, yet it must nevertheless be shaped into a product that is both safe and of consistent quality.

She adds that the product is inherently intricate: unlike small molecules, extracellular vesicles carry a cargo of thousands of lipid, protein, and metabolite species along with DNA and RNA, any of which could exert an effect after delivery to a target organ.

Swapping expensive omics for a targeted assay panel

As the company advances toward clinical development, it reports having built a manufacturing approach built around a set of assays that rely on standardized methods — ELISA and Western Blot among them — enabling QC of product batches that is both efficient and sustainable, thereby addressing the complexity problem.

“We can’t do omics on every single batch of product we are going to release because it would become too expensive down the line,” Silva explains. “We’ve been looking at the molecular data generated at the omics level and then selecting specific targets to pass that into the simpler QC panel.”

While the selected targets and QC panel are tailored to this particular product, Silva expressed hope that the broader takeaways will serve as inspiration for other companies building their own QC programs.

The potency problem the industry still has to solve

Going forward, she says a future challenge for the EV industry will be developing potency assays.

“Potency assay development for GMP production, so you can use your product in later clinical phases, is still something that needs a lot of development because EVs are such a complex modality,” she says.

As companies work toward getting an EV product to clinic, she says we can definitely see strategies emerging for what might be the right way to go.

What this means for regulators and patients on both sides of the Atlantic

A QC workflow that runs on standardized, widely available techniques makes it easier for developers to gather data.

Approach What it measures Practical role
Omics-level profiling Molecular data generated at the omics level Research-stage characterization; too expensive down the line, per Silva
Standardized QC panel (ELISA, Western Blot) Specific targets to pass that into the simpler QC panel Routine batch release testing; efficient and sustainable per the company
Potency assay (still to be developed) Potency assay for GMP production Required for later-phase clinical production; a future challenge for the EV industry

Where the field goes from here

Exogenus, whose pipeline currently focuses on inflammatory and degenerative conditions, reports that it has put in place a production and quality-control (QC) workflow capable of converting its complex, high-throughput analytics into an assay panel that is more sustainable to run.

“As companies work toward getting an EV product to clinic, we can definitely see strategies emerging for what might be the right way to go,” Silva says.

References

  • Exogenus Therapeutics — report on EV production and QC workflow, and comments by Andreia Silva, PhD, at Cell & Gene Therapy International Europe.

Consult a qualified healthcare professional regarding any treatment decisions.

Photo of author

Health Desk

Health Desk at Archyde.

OpenAI Pauses Frontier Training After Model Exploits DNS Misconfiguration